Natera, Inc. (NTRA) is a leading genetic testing and diagnostics company. Established in 2004 and headquartered in San Carlos, California, the company holds a significant position in the field of reproductive health and oncology. Natera is one of the pioneering entities in applying artificial intelligence (AI) and bioinformatics to reproductive health and cancer, enhancing disease management through genetic testing.
Natera offers a range of high-quality genetic testing services, each designed to provide critical health information. These tests assist healthcare professionals in managing their patient's health more effectively. Notably, they have developed non-invasive prenatal tests (NIPT), which can detect fetal chromosomal abnormalities as early as nine weeks into the pregnancy. Additionally, Natera offers genetic-carrier screening and advanced diagnostic services involving miscarriages and failures in vitro fertilization (IVF).
The company's innovative approach is also reflected in the field of oncology. They developed a kidney transplantation rejection test, and more recently, the company introduced the Signatera test, a personalized and tumor-informed DNA test used for the early detection of cancer recurrence.
Natera's team, made up of top data scientists, laboratory scientists, software engineers, and clinical professionals, are committed to improving patient care and outcomes through cutting-edge genetic testing. Their mission is to change the face of management in disease through genetic testing, using innovation as their springboard.
The company is marked also by its commitment to research and development. They have over 200 issued patents and collaborations with leading academic institutions to develop, validate, and broaden the clinical application of its tests.
As of 2019, Natera operates in over 50 countries and continues to grow its international presence. Natera's shares are traded on the NASDAQ Stock Market under the ticker symbol "NTRA".
In summary, Natera, Inc. is a global company that continues to redefine genetic testing in reproductive health and cancer. Its innovative and personalized approach to diagnostics not only improves patient care but also positions Natera as a leader in the drive toward precision medicine.